Antiretroviral activity and pharmacokinetics properties of lamivudine and zidovudine association;Atividade anti-retroviral e propriedades farmacocinéticas da associação entre lamivudina e zidovudina

Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences

Volumn 40, Issue 1, 2004, Pages 9-19

  De Souza, Jacqueline ^a   Storpirtis, Sílvia ^b  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antiretroviral drugs; Lamivudine; Pharmacokinetics; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; FLUCONAZOLE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; TRANSCRIPTASE; ZIDOVUDINE;

ANEMIA; ANTIVIRAL ACTIVITY; BIOTRANSFORMATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; FETUS CIRCULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE WALL; NONHUMAN; PLACENTA; REVIEW; SIDE EFFECT; URINARY EXCRETION; VIRUS LOAD; VIRUS MUTANT;

EID: 4043161323     PISSN: 15169332     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-93322004000100004     Document Type: Review

References (43)

1. ACOSTA, E. P.; PAGE, L. M.; FLETCHER, C. V. Clinical pharmacokinetics of zidovudine. Clin. Pharm., v. 30, n. 4, p. 251-262, 1996.
2. AMATO NETO, V.; MEDEIROS, E. A. S.; KALLAS, E. G.; LEVI, G. C.; BALDY, J. L. S.; MEDEIROS, R. S. S. AIDS na prática médica. São Paulo: Sanvier, 1996. 153p.
3. AOKI, F. Y. Infecções virais. In: PAGE, C. P.; CURTIS, M. J.; SUTTER, M. C.; WALKER, M. J. A.; HOFFMAN, B. B. Farmacologia Integrada. São Paulo: Manole, 1999. p. 445-460.
4. AYMARD, G.; LEGRAND, M.; TRICHEREAU, N.; DIQUET, B. Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography. J. Chromatogr. B, v. 744, p. 227-240, 2000.
5. BALINT, G. A. Antiretroviral therapeutic possibilities for human immunodeficiency virus/acquired imunodeficiency syndrome. Pharmacol. Ther., v 89, p. 17-27, 2001.
6. BARRY, M.; MULCAHY, F.; MERRY, C.; GIBBONS, S.; BACK, D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin. Pharmacokinet., v. 36, n. 4, p. 289-304, 1999.
7. BLUM, R.; LIAO, H. T. S.; GOOD, S. S.; MIRANDA, P. Pharmacokinetics and biovailability of zidovudine in humans. Am. J. Med., v. 85, S. 2A, p. 189-194, 1988.
8. BRASIL. Ministério da Saúde. Boletim epidemiológico - editorial. Disponível em 〈http://www.aids.gov.br/sitebol/inferior. htm〉. Acesso em: 01 de julho de 2002a.
9. BRASIL. Ministério da Saúde. Documentos, recomendações e relatórios técnicos. Disponível em 〈http://www.aids.gov.br/documentos.htm〉. Acesso em: 01 de julho de 2002b.
10. COHN, J. A. Recent advances HIV-1 infection -I. BMJ., v. 314, p. 487-491, 1997.
11. CONNOR, E. M.; SPERLING, R.; GELBER, R.; KISELEV, P.; SCOTT, G.; O'SULLIVAN, M. J.; VANDYKE, R.; BEY, M.; SHEARER, W.; JACOBSON, R. L.; JIMENEZ, E.; O'NEILL, E.; BAZIN, B.; DELFRAISSY, J. F.; CULNANE, M.; COOMBS, R.; ELKINS, M.; MOYE, J.; STRATTON, P.; BALSLEY, J. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatement. N. Engl. J. Med., v. 331, p. 1173-1180, 1994.
12. ERON, J. J.; YETZER, E. S.; RUANE, P. J.; BECKER, S.; SAWYERR, G. A.; FISHER, R. L.; TOLSON, J. M.; SHAEFER, M. S. Efficacy, safety and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS., v. 14, n. 6, p. 671-681, 2000.
13. FERNADES, C. Estudo de equivalência farmacêutica de comprimidos de lamivudina 150 mg. Belo Horizonte, 2001. 189 p. (Dissertaçãode Mestrado. Faculdade de Farmácia, Universidade Federal de Minas Gerais).
14. FLETCHER, C. V; RAWLE, S. P.; KAKUDA, T. N.; ANDERSON, P. L.; WELLER, D.; LANE, R. B.; BRUNDAGE, R. C.; REMMEL, R. P. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS, v. 14, n. 14, p. 2137-2144, 2000.
15. FRIJUS-PLESSEN, N.; MICHAELIS, H. C.; FOTH, H.; KAHL, G. F. Determination of 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, 3'-fluoro-3'- deoxythymidine and 2',3'-dideoxyinosine in biological samples by high-performance liquid chromatography. J. Chromatogr. Biom. Appl., v. 534, p. 101-107, 1990.
16. GLAXO - editorial. Disponível em 〈 http://www.glaxo.com. br〉. Acesso em: 01 de julho de 2002.
17. GULICK, R. M.; MELLORS, J. W.; HAVLIR, D.; ERON, J. J.; GONZALEZ, C.; McMAHON, D.; RICHMAN, D. D.; VALENTINE, F. T.; JONAS, L.; MEIBOHM, A.; EMINI, E. A.; CHODAKEWITZ, J. A. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med., v. 337, n. 11, p. 734-739, 1997.
18. HAVLIR, D. V.; LANGE, J. M. A. New antivirals and new combintions. AIDS, v. 12, Sup. A, p. S165-S174, 1998.
19. HARKER, A. J.; EVANS, G. L.; HAWLEY, A. E.; MORRIS, D. M. High-performance liquid chromatographic assay for 2'-deoxy-3'-thiacutidine in human serum. J. Chromatogr. B: Biom. Appl., v. 657, p. 227-232, 1994.
20. HENRY, K.; ERICE, A.; TIERNEY, C.; BALFOUR JR, H. H.; FISCHL, M. A.; KMACK, A.; LIOU, S. H.; KENTON, A.; HIRSCH, M. S.; PHAIR, J.; MARTINEZ, A.; KAHN, J. O. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. J. Acquir. Imm. Defic. Synd. and human retrovirol., v. 19, n. 4, p. 339-349, 1998.
21. HOETELMANS, R. M. W.; PROFIJT, M.; MEENHORST, P. L.; MULDER, J. W.; BEIJNEN, J. H. Quantitative determination of (-)-2'-deoxy-3'-thiacytidine (lamivudine) in human plasma, saliva and cerebrospinal fluid by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B., v. 713, p. 387-394, 1998.
22. HORNEFF, G.; ADANS, O.; WAHN, V. Pilot study of zidovudine-lamivudine combination therapy in vertical HIV-infected antiretroviral-naive children. AIDS, v. 12, n. 5, p. 489-494, 1998.
23. JOHNSON, M. A.; MOORE, K. H. P.; YUEN, G. J.; BYE, A.; PAKES, G. E. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet., v. 36, n. 1, p. 41-66, 1999.
24. JOZWIAKOWSKI, M. J.; NGUYEN, N. A. T.; SISCO, J. M.; SPANCAKE, C. W. Solubility behavior of lamivudine crystal forms in recrystallization solvents. J. Pharm. Sci., Washington, v. 85, n. 2, p. 193-199, 1996.
25. KEWN, S.; VEAL, G. J.; HOGGARD, P. G.; BARRY, M. G.; BACK, D. J. Lamivudine (3TC) phosphorylation and drug interations in vitro. Biochem. Pharmacol., v. 54, p. 589-595, 1997
26. KING, R. J.; KIMBERLIN, D. W.; ALDROVANDI, G. M.; ACOSTA, E. P. Antiretroviral pharmacokinetics in the paediatric population. Clin. Pharmacokinet., v. 44, n. 14, p. 1115-1133, 2002.
27. KYOKO, H.; ETSUKO, U.; MASUMITSU, T. Physicochemical properties and stability of Epivir tablets. Kagaku Ryoho no Ryoiki, Osaka, v. 13, p. 1170-1172, 1997.
28. LEGRAND, M.; COMETS, E.; AYMARD, G.; TUBIANA, R.; KATLAMA, C.; DIQUET, B. An in vivo pharmacokinetic/pharmacodynamic model for antiretroviral combination. HIV Clin. Trials., v. 4, n. 3, p. 170-83, 2003.
29. MANDELBROT, L.; LANDREAU-MASCARO, A.; REKACEWICZ, C.; BERRBI, A., BÉNIFLA, J. L.; BURGARD, M.; LACHASSINE, E.; BARRET, B.; CHAIX, M. L.; BONGAIN, A., CIRARUVIGNERO, N.; CRENNHEBRT, C.; DELFRAISSY, J. F.; ROUZIOUX, C.; MAYAUX, M. J.; BLANCHE, S. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA, v. 285, n. 16, p. 2083-2093, 2001.
30. MESPLET, N.; MORIN, P.; FRANÇOIS, C. AGROFOGLIO, L. A. Simultaneous quantification of nicleoside HIV-1 reverse transcriptase inhibitors by short-end injection capillary eletrochromatography on a β-cyclodextrin- blonded silica stationary phase. J. Chromatogr. A., v. 927, p. 161-168, 2001.
31. MOODLEY, J.; MOODLEY, D.; PILLAY, K.; COOVADIA, H.; SABA, J.; VAN LEEUWEN, R.; GOODWIN, C.; HARRIGAN, P. R.; MOORE, K. H.; STONE, C.; PLUMB, R.; JOHNSON, M. A. Pharmacokinetics and antiretroviral activity of lamivudine alone or when co-administered with zidovudine in HIV-infected pregnant women and their offspring. J. Infect. Dis., v. 178, p. 1327-1333, 1998.
32. MONTANER, J. S. G.; REISS, P.; COOPER, D.; VELLA, S.; HARRIS, M.; CONWAY, B.; WAINBERG, M. A.; SMITH, D.; ROBINSON, P.; HALL, D.; MYERS, M.; LANGE, J. M. A. A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients. JAMA, v. 279, n. 12, p. 930-937, 1998.
33. MOORE, J. D.; VALETTE, G.; DARQUE, A.; ZHOU, X. J.; SOMMADOSSI, J. P. Simultaneous quantitation of the 5'- triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry. J. Am. Soc. Mass Spectrom., v. 11, p. 1134-1143, 2000.
34. MOORE, K. H. P.; BARRETT, J. E.; SHAW, S.; PAKES, G. E.; CHURCHUS, R.; KAPPOR, A.; LLOYD, J.; BARRY, M. G.; BACK, D. The pharmacokinetics of lamivudine phosphorilation in peripheral blood mononuclear cells from patients infected HIV-1. AIDS, v. 13, n. 16, p. 2239-2250, 1999.
35. MOORE, K. H. P.; SHAW, S.; LAURENT, A. L.; LLOYD, P.; DUNCAN, B.; MORRIS, D. M.; O'MARA, M. J.; PAKES, G. E. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J. Clin. Pharmacol., v. 39, p. 593-605, 1999.
36. MOYER, T. P.; TEMESGEN, Z.; ENGER, R.; ESTES, L.; CHARLSON, J.; OLIVER, L.; WRIGHT, A. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin. Chem., v. 45, n. 9, p. 1465-1476, 1999.
37. PEREIRA, A. S.; KENNEY, K. B.; COHEN, M. S.; HALL, J. E.; ERON, J. J.; TIDWELL, R. R.; DUNN, J. A. Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography and tandem mass spectrometry. J. Chromatogr. B., v. 742, p. 173-183, 2000.
38. PERRY, C. M.; FAULDS, D. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs, v. 53, n. 4, p. 657-680, 1997.
39. STYRT, B. A.; PIAZZA-HEPP, T. D.; CHIKAMI, G. K. Clinical toxicity of antiretroviral nucleoside analogs. Antiv. Res., v. 31, p. 121-135, 1996.
40. SIMON, V. A.; THIAM, M. D.; LIPFORD, L. C. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography. J. Chromatogr. A., v. 913, p. 447-453, 2001.
41. VEAL, G. J.; HOGGARD, P. G.; BARRY, M. G.; KHOO, S.; BACL, D. J. Interation between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorilation. AIDS., v. 10, n. 5, p. 546-548, 1996.
42. VEAL, G. J.; BACK, J. D. Metabolism of zidovudine. Gen. Pharmacol., v. 26, n. 7, p. 1469-1475, 1995.
43. ZHOU, X. L.; SOMMADOSSI, J. P. Rapid quantitation of (-)-2'-deoxy-3'- thiacytidine in human serum by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B., v. 691, p. 417-424, 1997.